Like many cancers, acute myeloid leukemia (AML) has been a major beneficiary from the introduction of targeted therapies into the oncology treatment landscape. In fact, 1 of the earliest uses of ...
The FDA has cleared the investigational new drug (IND) application for NPX372, a first-in-class T-cell engager (TCE) for the ...
Usmani, MD, MBA, discussed the significance of phase 1 outcomes of gintemetostat therapy for patients with heavily pretreated ...
FDA approves pembrolizumab with chemotherapy for platinum-resistant ovarian cancer, showing significant survival benefits in ...
The central finding was the superior activity of a 2-antibody combination against the type 1 mutant CALR neoantigen. Dual ...
SEER-Medicare data show just 4% of older adults with blood cancers enter clinical trials, revealing disparities and fixable ...
Pellini notes that Hispanic patients often exhibit a higher incidence of specific genomic alterations in their cancers.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results